Performance

MK-677

Also known as: Ibutamoren, MK-0677, Nutrobal

RouteOral

UK StatusMK-677 occupies a complex regulatory position in the UK that requires careful navigation for legal compliance. The MHRA has not approved MK-677 as a medicine for human use, and it lacks marketing authorisation. The compound is not approved by the MHRA for human consumption and should not be used for this purpose. Importantly, it is not controlled under the Misuse of Drugs Act 1971, distinguishing it from anabolic steroids and other scheduled substances. This means personal possession is not illegal, but commercial supply for human consumption remains restricted. MK-677 is not listed as a prescription-only medicine (POM), nor is it classified as a controlled substance. However, the MHRA considers it an unlicensed medicinal product when sold for human use, making commercial supply without appropriate licensing potentially illegal under the Human Medicines Regulations 2012. The compound is sometimes available as a "research chemical" with appropriate disclaimers, though the MHRA has increased scrutiny of such sales since 2021. Quality control becomes critical when sourcing, as purity and dosing accuracy can vary significantly between suppliers. The regulatory environment remains fluid. The MHRA continues monitoring novel compounds sold online and has issued warnings about purchasing unlicensed medicines. Whilst MK-677 hasn't faced specific enforcement action, users should monitor MHRA communications for potential regulatory changes. It's crucial to understand that MK-677 is not approved for human consumption in the UK and any use carries inherent legal and safety risks. For comprehensive information on navigating UK regulations, consult our detailed [UK peptide legality guide](/learn/uk-peptide-legality), which covers current enforcement practices and legal considerations for research compounds.

Overview

MK-677 (ibutamoren) stands apart in the peptide research community — it's not actually a peptide at all, but a small molecule that mimics ghrelin to elevate growth hormone levels. Originally developed by Merck in the 1990s, MK-677 has become one of the most studied growth hormone secretagogues, with over two decades of clinical research examining its effects on body composition, sleep quality, and bone density.

Unlike injectable peptides such as [CJC-1295](/peptides/cjc-1295) or [Ipamorelin](/peptides/ipamorelin), MK-677 offers the convenience of oral administration with effects lasting up to 24 hours from a single dose. This makes it particularly attractive to researchers seeking the benefits of elevated growth hormone without the complexity of daily injections.

The compound works by binding to ghrelin receptors in the brain, triggering natural growth hormone pulses. Research by Svensson et al. (1998) demonstrates that 50mg daily increased 24-hour mean GH levels by 79% and IGF-1 by 82% in healthy young men, whilst clinical trials consistently show improvements in lean body mass over periods ranging from 8 weeks to 2 years, alongside improvements in sleep architecture — particularly REM sleep duration.

Researchers value MK-677 for its unique pharmacological profile. Unlike exogenous growth hormone, which can suppress natural production, MK-677 appears to preserve and amplify the body's natural GH pulses. This creates a more physiological pattern of hormone elevation, potentially reducing long-term suppression risks seen with other approaches.

The research community uses MK-677 primarily for body composition studies, sleep research, and anti-ageing investigations. Studies suggest potential recovery benefits, though controlled trials in athletic populations remain limited. The compound's ability to reverse age-related declines in growth hormone makes it particularly relevant for longevity research.

It's important to note that MK-677 is not approved by the MHRA for human consumption in the UK. The compound carries potential side effects including increased appetite and changes in glucose metabolism. For those interested in growth hormone enhancement research, MK-677 represents an alternative to traditional [peptide protocols](/learn/peptide-protocols), offering sustained effects with simplified administration, though proper research protocols and safety considerations remain essential.

Mechanism of Action

MK-677 functions as a selective agonist of the ghrelin receptor (GHSR1a), mimicking the action of the body's natural hunger hormone to trigger growth hormone release. The compound crosses the blood-brain barrier and binds to GHSR1a receptors in the hypothalamus and pituitary gland.

When MK-677 binds to these receptors, it activates phospholipase C, increasing intracellular calcium levels in somatotroph cells of the anterior pituitary. This cellular activation results in pulsatile growth hormone release that mimics natural physiological patterns, though with sustained elevation lasting up to 24 hours due to the compound's extended half-life of 4-6 hours.

What distinguishes MK-677 from peptide-based secretagogues like [GHRP-6](/peptides/ghrp-6) or [GHRP-2](/peptides/ghrp-2) is its oral bioavailability and extended duration of action. While peptide compounds require injection and have shorter durations, MK-677 provides convenience through oral administration whilst maintaining effectiveness.

The increased growth hormone subsequently signals the liver to produce insulin-like growth factor-1 (IGF-1), which mediates many of the compound's effects on muscle protein synthesis, bone formation, and tissue repair. Chapman et al. (1996) demonstrated that MK-677 increased IGF-1 levels by approximately 89% in elderly subjects, returning them to levels typical of younger adults.

Unlike synthetic growth hormone injection, which can suppress natural production, MK-677 works through the body's existing feedback mechanisms. This approach preserves the natural pulsatile pattern of GH release, potentially reducing the risk of receptor desensitisation associated with continuous hormone exposure.

The compound also increases IGF-binding protein-3 (IGFBP-3) and causes modest elevations in cortisol and prolactin levels. These secondary hormonal effects contribute to both the reported benefits and the side effect profile observed in clinical trials. Understanding this complete mechanism of action helps researchers design appropriate protocols and anticipate potential interactions with other [research compounds](/learn/research-compounds).